Neo-adjuvant chemotherapy in early stage non-small cell lung cancer.

Lung cancer treatment has evolved during the last decade from the non-specific cytotoxic drugs to targeted therapy. New diagnostic equipment such as the endobronchial ultrasound bronchoscopy and positron emission tomography has enhanced early lung cancer diagnosis. However; we still need additional novel biomarkers to assist the already used diagnostic techniques.

Feasibility and effectiveness of inhaled carboplatin in NSCLC patients.

Background: Inhaled chemotherapy is under investigation as an alternative therapeutic modality for Non-Small Cell Lung Cancer.

Methods: 60 NSCLC patients were randomized into 3 groups in this study. 20/60 patients (group A-control group) received I.

The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.

Bone metastases occur in 20-40% of patients with lung cancer. Recent studies demonstrate a direct antiproliferative effect of 3rd generation bisphosphonates (BPs) on lung tumors, which may influence the survival. Therefore, we examined the clinical impact of zoledronic acid (ZOL; Zometa), a 3rd generation BP, with a focus on the survival, time to progression and pain effect in lung cancer patients with bone metastases.